Alexium’s flame-retardant mattress sock passes US flammability testing
Alexium International Group Limited (ASX:AJX) today announced that prototype foam mattresses using flame retardant (FR) socks treated with Alexiflam® NF have passed flammability testing required by US federal safety standards.
Currently, foam mattresses require a FR sock that is made from glass fibre, which is expensive and comes with environmental and safety risks. Alexium is leveraging its proprietary flame retardant for cotton and cellulose-based textiles, Alexiflam® NF, for application to a cotton/polyester blend mattress sock. The Alexium product will be lower cost and safer than incumbent products.
As regulated by the United States Consumer Product Safety Commission, the testing — conducted by an independent third party, Underwriter Laboratories — confirmed that the barrier treated with Alexiflam® NF met all regulatory requirements (US federal safety standards in 16 CFR 1633) and passed the rigorous flammability test protocol.
Alexiflam® NF technology enables a cotton-based, sustainable and safe solution and removes problematic fiberglass shards out of the bedroom.
Flame-retardant treatments reduce the chances of a fire starting and delay the spread of fire once it starts.
Allen Reihman, Alexium’s Chief Commercial Officer said, “Current FR sock solutions use fiberglass technology to pass fire standards. Consumers are concerned with the health effects of shards of tiny glass that can migrate through the home.”
Mattress suppliers and brands are seeking solutions to this problem, and Alexium looks to have the solution given that socks treated with Alexiflam® NF contain no fiberglass. By treating natural cotton instead of synthetic materials, Alexiflam® NF provides a solution that is both sustainable and safe. Moreover, Alexiflam® NF solutions are more affordable than fiberglass alternatives.
Alexium Chief Executive Officer, Dr Robert Brookins, said “Passing this critical safety test is a major milestone in our commercialisation of Alexiflam® NF and validates our unwavering focus on innovation.”
“We’re progressing according to our growth plan by demonstrating our ability to successfully bring new product solutions to market quickly that align with customer needs. At this stage Alexium will begin working with new and existing customers on how they can use the FR cotton socks in their product lines.”
Today’s announcement follows news in late April that the company had signed a Supply and Evaluation Agreement with Israel Chemicals Ltd (TASE/NYSE: ICL), a leading global specialty minerals and specialty chemicals company, following a long period of co-operation between the two.
Being a major flame retardant chemical company, ICL will act as a strategic business partner for the market launch of Alexiflam® NF.
View Our Investment Portfolios
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction
is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.
